Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337070 | 1.00 | HSD17B10 (0.52) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| Hydrochloric Acid SCHEMBL31505485 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| Water SCHEMBL4953290 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL29299554 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL472190 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL472213 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| Hydrochloric Acid SCHEMBL4441607 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL306395 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| Hydrochloric Acid SCHEMBL1373260 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL934786 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 880 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | claimed |
| EP-4648849-A1 | NMU RECEPTOR 2 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2025-11-19 | — | — | EP | claimed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | claimed |
| US-20250133947-A1 | Thermal Evaporation-Growth of Halide Perovskites Through Phosphonic Acid Addition | GEORGIA TECH RES INST (US) | 2025-04-24 | — | — | US | claimed |
| CN-119752387-A | Aldehyde-free polyurethane adhesive for high-conductivity leather products containing imidazole heterocycle ionic liquid and preparation method thereof | 广东菲安妮皮具股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| WO-2025063849-A2 | DIMERIC FAP TARGETING AGENTS | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2025-03-27 | — | — | WO | claimed |
| CN-119060466-B | Preparation process of impact-resistant insulating plate | 山东澳兴绝缘材料有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119060466-A | Preparation process of impact-resistant insulating plate | 山东澳兴绝缘材料有限公司 | 2024-12-03 | — | — | CN | claimed |
| EP-4448544-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-10-23 | — | — | EP | claimed |
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-22 | — | — | US | claimed |
| EP-1587795-A1 | N- (1-BENZYL-2-OXO-2- (1-PIPERAZINYL) ETHYL) -1-PIPERIDINCARBOXAMID-DERIVATIVES AND RELATED COMPOUNDS USE AS CGRP-ANTAGONISTS FOR TREATING A HEADACHE | Boehringer Ingelheim International GmbH (DE) | 2005-10-26 | — | — | EP | claimed |
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2004-12-16 | — | — | US | claimed |
| WO-2004063171-A1 | N- (1-BENZYL-2-OXO-2- (1-PIPERAZINYL) ETHYL) -1-PIPERIDINCARBOXAMID-DERIVATIVES AND RELATED COMPOUNDS USE AS CGRP-ANTAGONISTS FOR TREATING A HEADACHE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | WO | claimed |
| US-20040136906-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2004-07-15 | — | — | US | claimed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | claimed |
| US-6147183-A | Amphoteric amine based polymers having a net cationic charge and process for their production | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-14 | — | — | US | claimed |
| US-5614535-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-03-25 | — | — | US | claimed |
| EP-0147608-B2 | PROCESS FOR THE PREPARATION OF TITANIUM DIOXIDE | BAYER AG (DE) | 1991-04-17 | — | — | EP | claimed |
| EP-0147608-B1 | PROCESS FOR THE PREPARATION OF TITANIUM DIOXIDE | BAYER AG (DE) | 1987-08-12 | — | — | EP | claimed |
| US-4663131-A | Process for the preparation of titanium dioxide | BAYER AKTIENGESELLSCHAFT (DE) | 1987-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, GPR18 | HSD17B10 2488/4885CHRM5 210/4885CHRM3 100/4885 |
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | GRPR, MLNR, NPBWR1 | HSD17B10 4878/4885CHRM5 442/4885CHRM3 286/4885 |
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, NMBR | HSD17B10 3645/4885CHRM5 161/4885CHRM3 190/4885 |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | HSD17B10 3729/4885CHRM5 3957/4885CHRM3 3959/4885 |
| US-20040136906-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, MLNR | HSD17B10 4863/4885CHRM5 1036/4885CHRM3 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.